HRS-4029
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 01, 2026
The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients
(clinicaltrials.gov)
- P2 | N=340 | Not yet recruiting | Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
New P2 trial • Cardiovascular • Ischemic stroke
1 to 1
Of
1
Go to page
1